Global Brucellosis Market Research Report - Forecast to 2023

Brucellosis market research report– by species (Brucella suis, B. abortus, B. melitensis), by diagnosis (serological tests, molecular techniques, bone marrow biopsy, CT, MRI), by treatment (vaccine, antibiotics), by end user– Global forecast till 2023

ID: MRFR/HC/3722-HCR | February 2021 | Region: Global | 90 pages

Market Scenario:


Brucellosis is a bacterial infection that spreads from animals to people most often via unpasteurized milk, cheese and other dairy products. More rarely, the bacteria that cause brucellosis can spread through the air or through direct contact with infected animals. The infection can usually be treated successfully with antibiotics. Avoiding unpasteurized dairy products and taking precautions while working with animals or in pathogy laboratories may prevent brucellosis. The global burden of human brucellosis remains enormous as the organism causes more than 500,000 infections per year worldwide. Usually, brucellosis is more common in males than in females and are generally non occuring in infants.


Brucella are small aerobic intracellular organisms which localize in the reproductive organs of host animals, causing abortions and sterility. They usually spread through fliuds such as animal’s urine, milk, placental fluid, and others. To this day, 8 species have been identified, named primarily for the source animal or features of infection. Out of these, four species are significantly pathogenous to humans, these include Brucella melitensis (sheep, goats), Brucella suis (swine), Brucella abortus (buffalos, bison), Brucella canis (dogs)


In the U.S., the Nationwide eradication of brucellosis from domestic cattle and bison are carried out by governing bodies such as USDA, APHIS, Cooperative State Federal Program. Currently all 50 states as well as Puerto Rico and the U.S. Virgin Islands are brucellosis free. Any livestock market that has been approved by the State is handled under the supervision of the Cooperative State–Federal Brucellosis Eradication Program.


A Brucella abortus product that is approved by the Brucellosis Eradication Program and licensed under USDA for injection into cattle to enhance their resistance to brucellosis. The brucellosis vaccine is called RB51. Pasteurization has been proven to destroy the causative agent of Brucellosis. 


The global market of brucellosiss is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.


Intended Audience:


  • Brucellosiss Vaccine Suppliers

  • Brucellosiss Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation:


The brucellosiss is segmented on the basis of species, diagnosis,  treatment and end-users.


On the basis of species, the market is segmented into Brucella suis, Brucella abortus, Brucella melitensis, Brucella canis and others 


On the basis of diagnosis, market is segmented into serological tests, molecular techniques, bone marrow biopsy, X-rays, computerized tomography (CT), magnetic resonance imaging (MRI), cerebrospinal fluid culture, echocardiography and others. The serological tests is segmented into serum agglutination test, rose bengal test, lateral flow assay, compliment fixation test, coombs test, enzyme linked immuno sorbent assaym, and immunocapture-agglutination test (brucellacapt). The molecular techniques is segmented into Polymerase Chain Reaction (PCR), Loop- mediated isothermal amplification assay, Multiple Locus VNTR Analysis (MLVA) typing. The Polymerase Chain Reaction (PCR) is further classified into standard PCR, real time PCR, nested PCR, PCR based assays


On the basis of treatment market is segmented into antibiotics, vaccines, and others


On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.


Research Methodology


 Global Bio-emulsion Polymers Market Research Report- Forecast to 2023


Sources: Annual reports, Press release, White paper, and Company presentation


Regional Analysis:


The global brucellosiss market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.


The European brucellosis market is the largest market owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.


America is projected to hold the second largest share of the global brucellosis market as due to the eradication of these disease from the USA. Currently, fewer than 100 cases are reported annually to the Centers for Disease Control and Prevention (CDC) with approximately 60% of human brucellosis cases in the United States now occur in California and Texas.  Brucellosis has become rare in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock. Most cases of brucella infection in the U.S. is due to the consumption of imported unpasteurized dairy products from Mexico.


The Asia Pacific and the Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector. The heaviest disease burden lies in countries of the Mediterranean basin and Arabian Peninsula, and the disease is also common in India, Mexico, and South & Central America. In Africa, incidence rates of 1.2-70 cases per 100,000 people have been reported. In Africa, such endemic diseases are controlled through animal slaughter due to the fragile nature of the food supply.


Key Players


Some of key the players in the global brucellosiss market are Hester Biosciences Limited, ATA FEN Inc., Biogénesis-Bagó S.A., Biopharma, Biovet, Calier & Biologicos Laverlam, Merck Animal Health (MSD Animal Health), Colorado Serum Company, Indian Immunologicals Limited, Dollvet, Veterinary Technologies Corporation, China Animal Husbandry Co., Ltd. (CAHIC), LABIOFAM, BCG Vaccine Laboratory, and others.


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   7.8% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Species, Diagnosis, Treatment and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Hester Biosciences Limited, ATA FEN Inc., Biogénesis-Bagó S.A., Biopharma, Biovet, Calier & Biologicos Laverlam, Merck Animal Health (MSD Animal Health), Colorado Serum Company, Indian Immunologicals Limited, Dollvet, Veterinary Technologies Corporation, China Animal Husbandry Co., Ltd. (CAHIC), LABIOFAM, BCG Vaccine Laboratory, and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Favorable government policies for research
  • The presence of a large number of players


  • Frequently Asked Questions (FAQ) :


    brucellosiss market is projected to grow at approximately 7.8% CAGR during the assessment period (2017-2023).

    Favorable government policies for R&D required to discover breakthrough therapeutics and the presence of a large number of players, are major tailwinds pushing the growth of the global brucellosiss market.

    The lack of knowledge about the availability of treatments is a major growth impeder for the global brucellosiss market.

    Europe holds the largest share in the global brucellosiss market, followed by North America and the Asia Pacific, respectively.

    Hester Biosciences Limited, Biogénesis-Bagó S.A., ATA FEN Inc., Biopharma, Merck Animal Health (MSD Animal Health), Biovet, Calier & Biologicos Laverlam, Colorado Serum Company, Dollvet, Indian Immunologicals Limited, Veterinary Technologies Corporation, LABIOFAM, China Animal Husbandry Co., Ltd. (CAHIC), and BCG Vaccine Laboratory, are some of the top players operating in the global brucellosiss market.

    TABLE OF CONTENT


    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Brucellosis Market, by Species

    6.1 Introduction

    6.2 Brucella suis

    6.2.1 Market Estimates & Forecast, 2016 – 2023

    6.3 Brucella abortus

    6.3.1 Market Estimates & Forecast, 2016 – 2023

    6.4 Brucella melitensis

    6.4.1 Market Estimates & Forecast, 2016 – 2023

    6.5 Brucella canis

    6.5.1 Market Estimates & Forecast, 2016 – 2023

    6.5 Others

    Chapter 7. Global Brucellosis Market, by Diagnosis

    7.1 Introduction

    7.2 Serological tests

    7.2.1 Market Estimates & Forecast, 2017 – 2023

    7.2.2 Serum agglutination test

    7.2.2.1 Market Estimates & Forecast, 2017 – 2023

    7.2.3 Rose Bengal test

    7.2.3.1 Market Estimates & Forecast, 2017 – 2023

    7.2.4 Lateral flow assay

    7.2.4.1 Market Estimates & Forecast, 2017 – 2023

    7.2.5 Compliment fixation test

    7.2.5.1 Market Estimates & Forecast, 2017 – 2023

    7.2.6 Coombs test

    7.2.6.1 Market Estimates & Forecast, 2017 – 2023

    7.2.7 Enzyme linked immuno sorbent assay

    7.2.7.1 Market Estimates & Forecast, 2017 – 2023

    7.2.8 Immunocapture-agglutination test (brucellacapt)

    7.2.8.1 Market Estimates & Forecast, 2017 – 2023

    7.3 Molecular techniques

    7.3.1 Market Estimates & Forecast, 2017 – 2023

    7.3.2 Polymerase Chain Reaction (PCR)

    7.3.2.1 Market Estimates & Forecast, 2017 – 2023

    7.3.2.2 Standard PCR

    7.3.2.2.1 Market Estimates & Forecast, 2017 – 2023

    7.3.2.3 Real time PCR

    7.3.2.3.1 Market Estimates & Forecast, 2017 – 2023

    7.3.2.4 Nested PCR

    7.3.2.4.1 Market Estimates & Forecast, 2017 – 2023

    7.3.2.5 PCR based assays

    7.3.2.5.1 Market Estimates & Forecast, 2017 – 2023

    7.3.3 Loop- mediated isothermal amplification assay

    7.3.3.1 Market Estimates & Forecast, 2017 – 2023

    7.3.4 Multiple Locus VNTR Analysis (MLVA) typing

    7.3.4.1 Market Estimates & Forecast, 2017 – 2023

    7.4 Bone marrow biopsy

    7.4.1 Market Estimates & Forecast, 2017 – 2023

    7.5 X-rays

    7.5.1 Market Estimates & Forecast, 2017 – 2023

    7.6 Computerized tomography (CT)

    7.6.1 Market Estimates & Forecast, 2017 – 2023

    7.7 Magnetic resonance imaging (MRI),

    7.7.1 Market Estimates & Forecast, 2017 – 2023

    7.8 Cerebrospinal fluid culture

    7.8.1 Market Estimates & Forecast, 2017 – 2023

    7.9 Echocardiography

    7.9.1 Market Estimates & Forecast, 2017 – 2023

    7.10 Others

    Chapter 8. Global Brucellosis Market, by Treatment

    8.1 Introduction

    8.2 Antibiotics

    8.2.1 Market Estimates & Forecast, 2017 – 2023

    8.3 Vaccines

    8.3.1 Market Estimates & Forecast, 2017 – 2023

    8.4 Others

    Chapter 9. Global Brucellosis Market, by End User

    9.1 Introduction

    9.2 Hospitals & Diagnostic Centers

    9.2.1 Market Estimates & Forecast, 2017 – 2023

    9.3 Academic Institutes

    9.3.1 Market Estimates & Forecast, 2017 – 2023

    9.4 Pharmaceutical & Biotechnology Companies

    9.4.1 Market Estimates & Forecast, 2017 – 2023

    9.5 Others

    9.5.1 Market Estimates & Forecast, 2017 – 2023
    Chapter. 10 Global Brucellosis Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.1 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Rest of the The Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 Hester Biosciences Limited

    12.1.1 Company Overview

    12.1.2 Treatment Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 ATA FEN Inc.

    12.2.1 Company Overview

    12.2.2 Treatment Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Biogénesis-Bagó S.A.

    12.3.1 Company Overview

    12.3.2 Treatment Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Biopharma

    12.4.1 Company Overview

    12.4.2 Treatment/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Biovet

    12.5.1 Company Overview

    12.5.2 Treatment Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Calier & Biologicos Laverlam

    12.6.1 Company Overview

    12.6.2 Treatment Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Merck Animal Health

    12.7.1 Overview

    12.7.2 Treatment Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Colorado Serum Company

    12.8.1 Company Overview

    12.8.2 Treatment/Business Segment Overview

    12.8.3 Financial Overview

    12.8.4 Key Development

    12.8.5 SWOT Analysis

    12.9 Indian Immunologicals Limited

    12.9.1 Company Overview

    12.9.2 Treatment Overview

    12.9.3 Financial overview

    12.9.4 Key Developments

    12.10 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Pharmaceutical industry

    Chapter 14 Appendix
    LIST OF TABLES
    Table 1 Brucellosis Industry Synopsis, 2017 – 2023

    Table 2 Brucellosis Market Estimates and Forecast, 2017 – 2023, (USD Million)

    Table 3 Brucellosis Market by Region, 2017 – 2023, (USD Million)

    Table 4 Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 5 Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 6 Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 7 Brucellosis Market by End Users, 2017 – 2023, (USD Million)

    Table 8 North America Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 9 North America Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 10 North America Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 11 North America Brucellosis Market by End User, 2017 – 2023, (USD Million)

    Table 12 US Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 13 US Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 14 US Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 15 US Brucellosis Market by End User, 2017 – 2023, (USD Million)

    Table 16 Canada Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 17 Canada Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 18 Canada Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 19 Canada Brucellosis Market by End User, 2017 – 2023, (USD Million)

    Table 20 South America Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 21 South America Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 22 South America Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 23 South America Brucellosis Market by End User, 2017 – 2023, (USD Million)

    Table 24 Europe Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 25 Europe Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 26 Europe Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 27 Europe Brucellosis Market by End User, 2017 – 2023, (USD Million)

    Table 28 Western Europe Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 29 Western Europe Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 30 Western Europe Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 31 Western Europe Brucellosis Market by End User, 2017 – 2023, (USD Million)

    Table 32 Eastern Europe Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 33 Eastern Europe Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 34 Eastern Europe Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 35 Eastern Europe Brucellosis Market by End User, 2017 – 2023, (USD Million)

    Table 36 Asia Pacific Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 37 Asia Pacific Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 38 Asia Pacific Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 39 Asia Pacific Brucellosis Market by End User, 2017 – 2023, (USD Million)

    Table 40 The Middle East & Africa Brucellosis Market by Species, 2017 – 2023, (USD Million)

    Table 41 The Middle East & Africa Brucellosis Market by Diagnosis, 2017 – 2023, (USD Million)

    Table 42 The Middle East & Africa Brucellosis Market by Treatment, 2017 – 2023, (USD Million)

    Table 43 The Middle East & Africa Brucellosis Market by End User, 2017 – 2023, (USD Million)
    LIST OF FIGURES
    Figure 1 Research Process

    Figure 2 Segmentation for Brucellosis Market

    Figure 3 Segmentation Market Dynamics for Brucellosis Market

    Figure 4 Global Brucellosis Market Share, by Species 2016

    Figure 5 Global Brucellosis Market Share, by Diagnosis 2016

    Figure 6 Global Brucellosis Market Share, by Treatment, 2016

    Figure 8 Global Brucellosis Market Share, by Technology, 2016

    Figure 9 Global Brucellosis Market Share, by End Users, 2016

    Figure 10 Global Brucellosis Market Share, by Region, 2016

    Figure 11 North America Brucellosis Market Share, by Country, 2016

    Figure 12 Europe Brucellosis Market Share, by Country, 2016

    Figure 13 Asia Pacific Brucellosis Market Share, by Country, 2016

    Figure 14 The Middle East & Africa Brucellosis Market Share, by Country, 2016

    Figure 15 Global Brucellosis Market: Company Share Analysis, 2016 (%)

    Figure 16 Hester Biosciences Limited: Key Financials

    Figure 17 Hester Biosciences Limited: Segmental Revenue

    Figure 18 Hester Biosciences Limited: Geographical Revenue

    Figure 19 ATA FEN Inc.: Key Financials

    Figure 20 ATA FEN Inc.: Segmental Revenue

    Figure 21 ATA FEN Inc.: Geographical Revenue

    Figure 22 Biogénesis-Bagó S.A.: Key Financials

    Figure 23 Biogénesis-Bagó S.A.: Segmental Revenue

    Figure 24 Biogénesis-Bagó S.A.: Geographical Revenue

    Figure 25 Biopharma: Key Financials

    Figure 26 Biopharma: Segmental Revenue

    Figure 27 Biopharma: Geographical Revenue

    Figure 28 Biovet: Key Financials

    Figure 29 Biovet: Segmental Revenue

    Figure 30 Biovet: Geographical Revenue

    Figure 32 Calier & Biologicos Laverlam: Key Financials

    Figure 33 Calier & Biologicos Laverlam: Segmental Revenue

    Figure 34 Calier & Biologicos Laverlam: Geographical Revenue

    Figure 35 Merck Animal Health: Key Financials

    Figure 36 Merck Animal Health: Segmental Revenue

    Figure 37 Merck Animal Health: Geographical Revenue

    Figure 38 Colorado Serum Company: Key Financials

    Figure 39 Colorado Serum Company: Segmental Revenue

    Figure 40 Colorado Serum Company: Geographical Revenue

    Figure 41 Indian Immunologicals Limited: Key Financials

    Figure 42 Indian Immunologicals Limited: Segmental Revenue

    Figure 43 Indian Immunologicals Limited: Geographical Revenue



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.